HB Wealth Management LLC Grows Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

HB Wealth Management LLC increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 30.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,357 shares of the medical equipment provider’s stock after acquiring an additional 774 shares during the quarter. HB Wealth Management LLC’s holdings in Zimmer Biomet were worth $409,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Glenview Trust Co grew its holdings in Zimmer Biomet by 1.5% during the 2nd quarter. Glenview Trust Co now owns 5,564 shares of the medical equipment provider’s stock valued at $810,000 after buying an additional 84 shares in the last quarter. Bradley Foster & Sargent Inc. CT grew its holdings in Zimmer Biomet by 1.3% during the 4th quarter. Bradley Foster & Sargent Inc. CT now owns 6,452 shares of the medical equipment provider’s stock valued at $823,000 after buying an additional 85 shares in the last quarter. Pinnacle Associates Ltd. boosted its position in shares of Zimmer Biomet by 5.0% during the 3rd quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider’s stock valued at $227,000 after acquiring an additional 97 shares during the last quarter. Financial Advocates Investment Management boosted its position in shares of Zimmer Biomet by 3.8% during the 3rd quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock valued at $295,000 after acquiring an additional 97 shares during the last quarter. Finally, Meeder Advisory Services Inc. boosted its position in shares of Zimmer Biomet by 4.7% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,174 shares of the medical equipment provider’s stock valued at $281,000 after acquiring an additional 98 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

ZBH opened at $132.61 on Thursday. The business’s 50-day moving average is $125.25 and its two-hundred day moving average is $118.03. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $149.25. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. The firm has a market capitalization of $27.20 billion, a PE ratio of 27.12, a price-to-earnings-growth ratio of 2.35 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same quarter in the previous year, the firm earned $1.88 earnings per share. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.08 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.72%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio (DPR) is 19.63%.

Insider Buying and Selling

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the transaction, the vice president now directly owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.95% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ZBH. TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. Evercore ISI downgraded Zimmer Biomet from an “outperform” rating to an “inline” rating and lowered their price target for the stock from $135.00 to $125.00 in a research report on Thursday, January 4th. Raymond James raised their price target on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. StockNews.com downgraded Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. Finally, Barclays lifted their target price on Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research report on Monday, February 12th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $137.84.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.